$PBIO the company's revenue model that assumes $2.5 million in UST sales for 2020 (12 units) growing to $7.0 million by 2022. At the same time, management recognizes that the opportunity window in CBD may only last a few years before the industry begins to consolidate. The Company sees much greater opportunity outside CBD, particularly in food, pharmaceuticals and nutraceuticals and cosmetics.